Finasteride vs minoxidil: evidence-based comparison for androgenetic alopecia in 2026

Finasteride vs Minoxidil: Evidence-Based Comparison for Androgenetic Alopecia in 2026

Androgenetic alopecia (AGA), commonly known as hereditary pattern hair loss, affects at least 80% of men and about 50% of women by age 70. Two medications remain the absolute cornerstones of medical treatment approved by the European Medicines Agency and other global regulators: oral finasteride 1 mg and topical minoxidil (2% or 5% solutions). This article offers an evidence-based comparison grounded in peer-reviewed clinical trials and official product safety sheets.

Understanding Androgenetic Alopecia

Hair grows in distinct, repeating cycles: anagen (the active growth phase lasting 2 to 7 years), catagen (the brief transition phase), and telogen (the resting phase before shedding). In genetic hair loss, a powerful male hormone derivative called dihydrotestosterone (DHT), which is produced when the enzyme 5-alpha reductase type II converts regular testosterone, binds to receptors in the hair's control center (the dermal papilla cells) and shortens this vital growth phase. The result is follicular miniaturization, a process where thick, pigment-rich terminal hairs gradually shrink into thin, peach-fuzz vellus hairs. Crucially, DHT does not immediately destroy the hair follicles; it merely shrinks them, a process that remains partially reversible if treatment is initiated early.

How Finasteride Works

Finasteride acts as a competitive inhibitor of 5-alpha reductase type II, meaning it temporarily blocks the specific enzyme responsible for producing hair-damaging DHT. At a standard dosage of 1 mg daily, it reduces scalp DHT levels by 60% to 70% and blood serum DHT by 65% to 70%. Visible clinical improvements typically appear after 3 to 6 months of daily use and reach their peak at 1 to 2 years. The treatment works most effectively on the crown (vertex) of the head, whereas the response at the frontal hairline is generally more modest. Because finasteride is a disease-modifying treatment that targets the root cause of hair loss, stopping the medication allows DHT levels to rebound within weeks, gradually reversing any progress.

How Minoxidil Works

Minoxidil is a prodrug, which means it is inactive when applied and must be converted into its active form, minoxidil sulfate, by a local enzyme called sulfotransferase SULT1A1 found in the hair's outer root sheath. Once fully activated, it opens ATP-sensitive potassium channels, which alters cell membrane voltages, lowers calcium levels inside the cells, prolongs the active growth phase, and promotes the survival of hair-producing cells through specific cellular survival signaling pathways (specifically the ERK, Akt, and Bcl-2 pathways). While it is widely known to widen blood vessels, this vasodilation is actually a secondary consequence rather than the primary way it stimulates growth. Because an estimated 30-40% of users have low sulfotransferase activity, they lack the necessary enzyme levels to activate the drug, causing them to respond poorly even with perfect daily adherence.

Head-to-Head Efficacy

A robust Bayesian network meta-analysis, which is an advanced statistical review that compares multiple different treatments, published in JAMA Dermatology (Gupta et al., 2022) pooled data from 23 individual monotherapy trials:

At the 24-week mark, a daily dose of 5 mg oral minoxidil produced the greatest increase in thick terminal hairs, outperforming 1 mg of oral finasteride by an average of 10.4 hairs per square centimeter. Furthermore, a Chinese Randomized Controlled Trial (RCT), which represents the gold standard of clinical scientific studies, tracking 126 men over 12 months demonstrated the following outcomes:

• Finasteride 1 mg: 80.5% improvement in hair density and appearance

• 5% topical minoxidil: 59% improvement in overall hair coverage

• Combination: 94.1% improvement, demonstrating a powerful synergistic effect

Long-Term Efficacy of Finasteride

In the landmark 5-year pivotal clinical trials, which were the main studies used to gain official approval for the drug: 48% of the treated men experienced a visible increase in hair density, 42% successfully stabilized their hair loss, and only 10% experienced visible worsening, compared to a substantial 75% who saw visible progression of their hair loss in the placebo group (those taking an inactive dummy pill). Ultimately, approximately 90% of the men treated with finasteride did not experience further visible hair loss over the course of 5 years, and observational data collected over 10 years suggest that around 86% of patients continue to enjoy long-term benefits.

Topical Minoxidil Expectations

For patients using topical minoxidil, initial improvements typically start to appear between weeks 6 and 8, reaching their peak efficacy around the 12th month before slowly reaching a plateau. For successful responders, this process results in a highly realistic improvement in hair density and coverage rather than a complete reversal of long-standing or advanced balding.

Side Effects

Finasteride 1 mg

These side effects are generally mild in nature, occur primarily during the first year of treatment, and usually resolve completely upon discontinuation, meaning when the patient stops taking the medication. While post-finasteride syndrome, which refers to persistent sexual, physical, or neuropsychiatric symptoms that continue after stopping the drug, has been reported, it is still considered clinically rare, and its underlying biological mechanism remains highly debated in the medical community. Patients with a personal history of clinical depression or baseline sexual dysfunction should discuss these risks openly and thoroughly with their prescribing physician before starting therapy.

Topical Minoxidil

• Local scalp irritation, which is often caused by the delivery solvent propylene glycol, though switching to a foam formulation usually avoids this issue

• Hypertrichosis, which refers to unwanted hair growth on nearby areas like the face or forehead, a side effect that is more commonly reported in female patients

• An initial temporary shedding phase occurring during weeks 2 to 8, which is caused by follicular synchronization as old hairs are pushed out to make way for a new, healthy growth cycle

• Rare systemic side effects, which may include headaches, mild dizziness, or a slightly elevated heart rate known as mild tachycardia

It is important to clarify that fluid retention and subsequent weight gain are not side effects associated with topical minoxidil; these effects are characteristic of oral minoxidil when used at higher, antihypertensive doses originally prescribed to manage high blood pressure.

Combination Therapy

Finasteride directly targets the underlying hormonal trigger of genetic hair loss, whereas minoxidil works independently to prolong the active hair growth phase, regardless of circulating androgen levels, which are male hormones. This strong biological complementarity explains why using both treatments together consistently outperforms monotherapy, which means using just one treatment alone, across numerous randomized clinical trials and comprehensive statistical meta-analyses.

What Happens If You Stop?

• Topical minoxidil: any hair gained through the treatment will shed, and the scalp typically returns to its baseline state, meaning the natural level of hair loss before starting therapy, within 3 to 6 months.

• Finasteride 1 mg: the therapeutic benefits begin to reverse by the 6-month mark and generally return to the pre-treatment baseline by 9 to 12 months.

The Women's Case

Currently, topical minoxidil remains the gold-standard, first-line option for treating female pattern hair loss. While the 2% solution is officially approved, the 5% foam version is widely recommended by dermatologists to help minimize the risk of facial hypertrichosis, which is unwanted facial hair growth. On the other hand, finasteride is strictly contraindicated in women of childbearing potential because of its severe teratogenic risk, meaning a high risk of causing birth defects in a developing male fetus. Furthermore, in postmenopausal women, who have completed menopause, the standard 1 mg daily dose has not demonstrated significant therapeutic efficacy in controlled clinical trials.

European Regulatory Context

Within the European Union, oral finasteride 1 mg remains strictly a prescription-only medication. In contrast, topical formulations of minoxidil in 2% and 5% concentrations are generally available over the counter, though seeking professional pharmacist counselling is highly recommended, as product availability and local pricing vary widely by member state.

Clinical Decision Framework

• Stage the severity of your hair loss using standard medical scales, such as the Norwood-Hamilton scale for male pattern baldness or the Ludwig scale for female hair thinning.

• Identify your dominant pattern of hair thinning: the vertex or crown of the head responds exceptionally well to oral finasteride, whereas diffuse thinning, which is hair loss spread evenly across the scalp, and receding frontal areas may benefit more from topical minoxidil.

• Evaluate your age and the current rate of hair loss progression: aggressive, early-onset genetic hair loss often warrants utilizing a combination of both treatments right from the start to achieve maximum efficacy.

• Discuss any medical contraindications, which are specific health reasons to avoid a drug, with your doctor, including a history of depression, existing sexual dysfunction, a planned conception, or cardiovascular comorbidities such as heart or blood vessel conditions.

• Establish a structured monitoring plan: this should include taking baseline photographs, scheduling standardized evaluations at 6 and 12 months, and establishing a baseline for Prostate-Specific Antigen (PSA) levels, a common blood test for prostate health that finasteride can lower, for men over the age of 40 on long-term therapy.

• Consider incorporating clinical adjuncts, which are supportive add-on therapies, such as scalp microneedling, low-level laser light therapy, PRP (Platelet-Rich Plasma therapy using concentrated growth factors from your own blood), ketoconazole shampoo, or low-dose oral minoxidil under medical supervision.

Conclusion

In conclusion, finasteride and minoxidil serve as highly complementary clinical tools that address different biological levels of genetic hair loss. While finasteride tends to produce greater overall gains in thick, terminal hair for men, topical minoxidil remains the gold-standard, first-line approach for women. Combining both therapies consistently outperforms using either treatment alone. Crucially, both treatments require indefinite, long-term use to maintain their effects and benefit significantly from being initiated early in the hair loss process. Modern tools such as Hairdex can help support your journey by providing standardized scalp mapping and high-resolution follow-up imaging, allowing you to obtain an objective, measurable assessment of your progress over time alongside your dermatologist or trichologist, a specialized medical expert in hair and scalp health.

FAQ

What is the difference between finasteride and minoxidil?

Finasteride is an oral prescription tablet that works by blocking the internal enzymatic production of the hair-thinning hormone DHT. In contrast, minoxidil is a topical solution or foam applied directly to the scalp that extends the active hair growth phase by opening cellular potassium channels. Because they target completely different biological mechanisms, they act on different levels of the same hair loss condition.

Which is more effective for male pattern hair loss?

At 48 weeks of treatment, clinical data from comprehensive network meta-analyses show that finasteride 1 mg produces approximately 26 to 32 more thick, fully-grown terminal hairs per square centimeter of scalp than topical minoxidil. However, combining both treatments has consistently been shown to outperform either medication used on its own.

Can finasteride and minoxidil be used together?

Yes, absolutely. Multiple high-quality Randomized Controlled Trials (RCTs) demonstrate that utilizing both treatments together produces significantly superior results compared to monotherapy, showing clinical hair improvement rates of up to 94.1%.

How long until I see results?

For topical minoxidil, initial signs of growth generally appear within 2 to 4 months, reaching peak results around the 12th month. For oral finasteride, stabilization of hair loss is typically observed within 3 to 6 months, with peak regrowth visible after 1 to 2 years of continuous use. It is completely normal and expected to experience a temporary shedding phase during the first 2 to 8 weeks of starting minoxidil as your follicles restart their growth cycle.

What happens if I stop?

Once treatment is discontinued, any hair gained or maintained will be lost. These benefits typically reverse within 3 to 6 months after stopping topical minoxidil, and within 9 to 12 months after stopping oral finasteride, at which point your hair loss will return to its natural progressive path.

Is finasteride safe for women?

Oral finasteride is strictly contraindicated, meaning it must never be used, in women of childbearing potential due to the high risk of causing severe birth defects in a male fetus. In postmenopausal women, who have completed menopause, clinical trials have shown that the standard 1 mg daily dose does not provide significant therapeutic benefit.

Do I need a prescription?

Yes. Across the vast majority of European countries, oral finasteride is strictly classified as a prescription-only medication requiring a doctor's evaluation. On the other hand, topical minoxidil is widely available over the counter without a prescription.

Is post-finasteride syndrome real?

Persistent sexual, physical, or mood symptoms continuing after discontinuation of the drug have indeed been reported by some patients, though these cases are clinically considered to be rare. The exact biological mechanism behind these persistent symptoms is not yet fully understood by medical science. It is highly recommended to openly discuss any history of mood disorders or sexual health concerns with your prescribing doctor before starting treatment.

References

[1] Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatology. 2022. Read the source

[2] Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic Alopecia: Therapy Update. Drugs. 2023. Read the source

[3] Kaiser M, Abdin R, Gaumond SI, Issa NT, Jimenez JJ. Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. Clinical, Cosmetic and Investigational Dermatology. 2023. Read the source

[4] Finasteride 1mg tablets, Summary of Product Characteristics (SmPC). electronic medicines compendium (emc). Read the source

[5] Sexual dysfunction associated with 5α-reductase inhibitors in the treatment of androgenetic alopecia: a systematic review. Frontiers in Medicine. 2026. Read the source

[6] Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. Journal of Cosmetic Dermatology. 2021. Read the source

[7] Müller Ramos P, Melo DF, Radwanski H, de Almeida RFC, Miot HA. Female-pattern hair loss: therapeutic update. Anais Brasileiros de Dermatologia. 2023. Read the source